Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc.CRBP · Entity 6261 | President and CSO | January 18, 2019 | January 18, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Corbus Pharmaceuticals Holdings, Inc.
Report date January 18, 2019 · Filed January 18, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option(right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.53 · Expires 2029-01-18 | Direct | 195,000 |
Reported balance
After 2019-01-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-18 · Grant · Acquired 195,000 · Balance 195,000 F1: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on January 18, 2020, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on February 18, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on January 18, 2020, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on February 18, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 18, 2019 Filed Jan 18, 2019 16:57 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option(right to buy) · Derivative | 195,000 | $0.00 Strike: $7.53 | $0.00 |
DisclosureSEC source: 0001209191-19-004574 · doc4.xml · derivative · entry 1 Tepper Mark · CIK 0001291087 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,000 Underlying: Common Stock · 195,000 shares Expires 2029-01-18 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on January 18, 2020, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on February 18, 2020. Read SEC document |
| November 14, 2018 Filed Nov 16, 2018 16:09 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | Exercise / conversionOption to purchase common stock · Derivative | 10,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001209191-18-058931 · doc4.xml · derivative · entry 2 Tepper Mark · CIK 0001291087 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,600 Underlying: Common Stock · 10,000 shares Expires 2024-04-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 14, 2018 Filed Nov 16, 2018 16:09 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | Exercise / conversionCommon Stock | 10,000 | $1.00 | $10,000.00 |
DisclosureSEC source: 0001209191-18-058931 · doc4.xml · nonDerivative · entry 1 Tepper Mark · CIK 0001291087 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,110,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2018 Filed Jan 5, 2018 17:28 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option(right to buy) · Derivative | 175,000 | $0.00 Strike: $8.35 | $0.00 |
DisclosureSEC source: 0001209191-18-002514 · doc4.xml · derivative · entry 1 Tepper Mark · CIK 0001291087 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2028-01-04 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on January 4, 2019, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on February 4, 2019. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 16:20 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option(right to buy) · Derivative | 115,000 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001209191-17-017496 · doc4.xml · derivative · entry 1 Tepper Mark · CIK 0001291087 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2027-03-01 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on March 1, 2018, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on April 1, 2018. Read SEC document |
| October 06, 2016 Filed Oct 7, 2016 16:52 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option(right to buy) · Derivative | 150,000 | $0.00 Strike: $8.71 | $0.00 |
DisclosureSEC source: 0001209191-16-145416 · doc4.xml · derivative · entry 1 Tepper Mark · CIK 0001291087 · President and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2026-10-06 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on October 6, 2017, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on November 6, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.